Review for Antimicrobial Peptides with Anticancer Properties
news

Review for Antimicrobial Peptides with Anticancer Properties: Re-purposing of Potential Anticancer Agents

Announcing a new article publication for BIO Integration journal. In this article the authors Zhong, Cuiyu; Zhang, Lei; Huang, Jiandong; Huang, Songyin; Yao, Yandan from Sun Yat-sen University, Guangzhou, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou, China and Shenzhen Institutes of Advanced Technology, Guangdong, China review antimicrobial peptides with anticancer properties.

There is considerable interest in a new class of anticancer molecules that is currently still under investigation termed the cationic antimicrobial peptides (AMPs). AMPs are a group of pervasive components of the innate immunity which can be found throughout all classes of life. The small innate peptides cover a broad spectrum of antibacterial activities due to their electrostatic interactions with the negatively charged bacterial membrane.

Compared with normal cells, cancer cells have increased proportions of negatively charged molecules, including phosphatidylserine, glycoproteins, and glycolipids, on the outer plasma membrane. This provides an opportunity for exploiting the interaction between AMPs and negatively charged cell membranes in developing unconventional anticancer strategies. Some AMPs may also be categorized into a group of potential anticancer agents called cationic anticancer peptides (ACPs) due to their relative selectivity in cell membrane penetration and lysis, which is similar to their interaction with bacterial membranes.

The authors review several examples of ACPs that are used in tumor therapy for their ability in penetrating or lysing tumor cell membrane and discuss recent advances and challenges in the application of ACPs.

Article reference: Zhong, Cuiyu; Zhang, Lei; Huang, Jiandong; Huang, Songyin; Yao, Yandan, Review for Antimicrobial Peptides with Anticancer Properties: Re-purposing of Potential Anticancer Agents, BIO Integration, 2020, https://doi.org/10.15212/bioi-2020-0013    

BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.

As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.

BIOI is now open for submissions; articles can be submitted online at:

https://mc04.manuscriptcentral.com/bioi

Please visit www.bio-integration.org to learn more about the journal.

Editorial Board: https://bio-integration.org/editorial-board/

BIOI is available on the IngentaConnect platform (https://www.ingentaconnect.com/content/cscript/bioi) and at the BIO Integration website (www.bio-integration.org).

Submissions may be made using ScholarOne (https://mc04.manuscriptcentral.com/bioi).

There are no author submission or article processing fees.

Follow BIOI on Twitter @JournalBio; Facebook (https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and LinkedIn (https://www.linkedin.com/company/bio-integration-journal/).

ISSN 2712-0074

eISSN 2712-0082